Exam 2 Flashcards

1
Q

L sided HF

A
  • Decreased contractility of LV
  • decreased SV, EF, and CO
  • increased EDV and LV EDP
  • can lead to pulmonary congestion/edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

R sided HF

A
  • Decreased contractility of RV

- accumulation of blood in RV, RA, and systematic circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CHF

A
  • Combo of R and L sided HF - overall decreased ventricular contractility
  • due to changes in myocardium, heart can’t meet metabolic demands
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HF staging

A

A: pre-HF
B: has disorder; no symptoms
C: has disorder and symptoms; medical management
D: has disorder and symptoms more advanced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Acute HF

A
  • 5 lb rule; gain 5 lbs in 24 hrs is an acute episode

- rapid onset of symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

systolic HF or HFrEF

A
  • REDUCED EF and oxygen delivery to tissues

- decreased LV contractility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

diastolic HF or HFpEF

A
  • preserved EF
  • ventricles lose their ability to relax and become stiffer and less compliant
  • chambers don’t fill normally during diastole
  • reduced volume capacity of chambers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ischemia

A

restricted/reduced blood flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

hypoxia

A

a condition in which a body/region is deprived of adequate O2 supply at the tissue level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hypoxemia

A

low O2 content in blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Acute Coronary Syndrome

A
  • non specific dx

- sudden decreased blood flow to heart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ischemic Heart disease

A
  • under ACS

- includes MIs, stable/unstable angina, atherosclerotic injury to coronary arteries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IHD diagnosis

A

cardiac enzymes, C-reactive proteins, homocysteine, abnormal lipid profile, brain natriurtic peptide, prothrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ischemic cardiomyopathy

A
  • ischemia to to heart muscles
  • causes decrease in contractility
  • if chronic, damage to myocytes is irreversible and cardiac remodeling occurs
  • ultimately may develop CHF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cardiac and RA

A
  • presence of RA is considered primary pathogenic factor for premature development of atherosclerosis
  • increased risk x3 of CV event
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IHD- angina

A

-intermittent chest pain caused by transient, reversible myocardial ischemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

stable angina

A
  • O2 delivery is not meeting O2 needs
  • onset: increased exertion of stress
  • occurs at PREDICTABLE HR
  • Tx with nitrates or decreased stress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

unstable angina

A
  • onset: exertion or stress
  • onset is UNPREDICTABLE
  • Tx with nitrates potentially
  • can occur due to plaque changes and/or coronary artery vasospasm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IHD- MI

A

Time is Tissue

-ischemic insult for long period of time leading to tissue damage and tissue/whole body death results

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

IHD- sudden cardiac death

A
  • cessation of cardiac function
  • Pathology ventricular fibrillation –> Asystole
  • Potential causes: quiet MI, acute coronary plaque rupture/thrombus, >60% narrowing of artery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IHD pathogenesis

A
  • originates from plaque in arterial lumen due to inflammation and lipid deposits
  • plaque rupture- exposes plaque to blood
  • occlusive event- damage dependent on coronary artery involved, time until treated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Poiseville’s Law

A
  • blood flow regulation
  • Q=chang in Pxr^4
  • if radius decreased, resistance increases, pressure increases
  • results in decreased blood flow
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Double product

A
  • blood flow regulation
  • DP= HR x systolic BP
  • tells us how hard the heart is working
  • could indicate co-existing CV conditions with risk of AE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Primary HTN

A

90% of all cases
no known cause
-progressive, decreased vascular compliance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Secondary HTN

A

caused by kidney conditions, arterial, heart, or endocrine conditions
10% of all HTN cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

HTN and Kidney disease

A
  • decreased blood delivery to kidney tissue
  • arteries around kidney narrow, weaken, and harden
  • decreased filtration; increased water retention
  • increased BP
  • increased pre-load
  • increased total peripheral resistance
  • decreased ability to control BP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

HTN and diabetes

A
  • elevated glucose levels damage glomerular filtration

- increased water retention and increased volume and BP

28
Q

HTN and heart disease

A
  • increased afterload - lead to thickened heart and thickened BV walls
  • causes changes in the heart making it less effective
  • LV progressively dilates and thins walls; leading to declining EF
29
Q

Cor Pulmonale

A
  • enlargement of R ventricle caused by pulmonary HTN

- chronic and progressive

30
Q

pulmonary HTN

A
  • causes cor pulmonale

- MAP >25 mmhg or systolic pressure >35mmHg

31
Q

lung diseases and CP

A
  • COPD
  • diffuses pulmonary interstitial fibrosis
  • collapsed lung
  • cystic fibrosis
  • PE
32
Q

Pulmonary vessels and CP

A
  • pulmonary vascular sclerosis

- drug, toxin, radiation induced vascular sclerosis

33
Q

CP Clinical Implications

A

PT- low impact, light-mod resistance

-try not to overexercise

34
Q

Assessment Criteria for taking BP

A
  • rest 5 min
  • legs uncrossed
  • feet on floor
  • arm supported
  • cuff size
  • cuff on bare arm
  • no talking
  • no phone/ reading
  • take BP on both arms
  • record higher BP reading
  • record which arm to use for future readings
35
Q

cardiomyopathy

A
  • disorder WITHIN the cardiac myocytes affecting performance
  • irreversible decline of cardiac function
  • long term pts often look for transplant
  • resulting in reduced EF
36
Q

dilated CM

A
  • most common form of myopathies
  • chamber dilation/enlargement along with contractile impairment
  • decreased EF and SV
  • dilated heart undergoes remodeling
  • LV “ballooning” causing dilation of other chambers
  • ultimately leads to HF
37
Q

dilated CM remodeling

A

-heavier than normal heart
-hypertrophies myocytes
-loss of myofibrils, reduced mitochondrial function
-fibrosis
thin-walled chambers

38
Q

causes of dilated CM

A
  • genetic mutations
  • viral infections - HIV
  • toxins- ETOH, cancer drugs, cocaine
  • metabolic disorder- DM, nutritional deficiencies, hyper/hypo thyroidism
  • myocarditis
39
Q

hypertrophic CM

A
  • most common cause of death
  • thickened LV with a non-dilated LV chamber
  • functionally defective myocytes- abnormally high BPs is THEIR normal BPs
  • LV and septal walls hypertrophy to compensate
  • ultimately heart will decompensated- decrease functional capacity and fail
40
Q

obstructive HCM

A

septal wall thickens and LV wall stiffens, obstructing blood flow into the aorta

41
Q

nonobstructive HCM

A

LV wall stiffens and reduces LV EDV and SV

-blood flow is not blocked

42
Q

HCM long term complications

A
  • atrial fibrillation
  • dysrhythmias
  • HF
  • Hx of MIs
43
Q

Restrictive/infiltrative CM

A
  • restrictive diastolic filling/ loss of compliance; chambers unable to expand
  • systolic function is normal
  • EDV and SV is reduced
  • ESVs and EFs normal
  • increased pressure in ventricular filling
44
Q

Restrictive CM causes

A
  • scleroderma
  • amyloidosis
  • sarcoidosis
  • Diabetes
  • hemochromatosis
  • Chemo agents
  • radiation exposure
45
Q

Pneumonia

A

-an acute lung injury where inflammatory process affects parenchyma of the lungs

46
Q

Pneumonia causes

A
  • bacterial, viral, and fungal infections
  • inhalations of toxins, chemicals, smoke, dists, gases
  • aspiration of food, fluids and vomit
47
Q

Pneumonia pathogenesis

A
  • inflammatory and immune responses with damaging SEs to lung tissue
  • endotoxins released that damage bronchial and alveolocapillary membranes
  • damage type II cells
48
Q

tuberculosis

A
  • mycobacterium tuberculosis
  • site of infection: lungs, vertebral column (Pott’s), CNS, heart
  • transmission: airborne; casual contact insufficient; household exposure over many months more likely
49
Q

tuberculosis progression

A
  • infection in lungs
  • epithelial cells surround and encapsulate replicated bacteria to limit further spread (granuloma)
  • TB in Ghon complex can be reactivated- secondary infection
  • cavity is formed in tissue where immune cells cant reach
  • pt becomes infectious
50
Q

Obstructive lung disease

A
  • conditions that makes it hard to EXHALE all the air in the lungs
  • caused by aspiration, PE, Emphysema/chronic bronchitis
  • Identified via pulmonary function tests
51
Q

COPD

A
  • Chronic obstructive pulmonary disease; a non-specific dx
  • includes emphysema, chronic asthma, and chronic bronchitis/small airways disease
  • 3rd leading cause of death
52
Q

COPD and spirometry

A
  • test pulmonary function and lung volumes
  • diagnostic and prognostic
  • Dx: FEV1/FVC ratio is <0.70 following bronchodilator administration
53
Q

FEV1

A

amount of air you can force OUT of your lungs in 1 sec

54
Q

FVC

A

total amount of air exhaled out of your lungs after taking a deep breath

55
Q

Obstructive Lung disease: emphysema

A

-pathologic accumulation of air in lungs; air is trapped in lungs
-Increase in residual volume, total lung capacity
decrease in FVC1/FVC ratio
-TLC- flattened diaphragm compromising function

56
Q

Emphysema causes

A
  • Genetic- Alpha-1 atitrypsin deficiency

- cigarette smoke- can affect alpha-1 atitrypsin function

57
Q

Effects of A-1 AT deficiency and cigarette smoking

A
  • destruction of individual alveoli
  • development of “super alveoli”- causes air trapping
  • destruction of connective tissue supports for the very smallest airways allowing them to collapse during expiration
58
Q

Emphysema FEV1/FEV

59
Q

Pink puffer

A
  • accompanied heart problems or cor pulmonale
  • ineffective cough
  • hypoxemia
  • hypercapnia- retaining CO2
  • chronic pumonary metabolic acidosis
  • deconditioning
60
Q

chronic bronchitis

A
  • productive cough lasting at least 3 months per year for 2 consecutive years
  • increased mucous production causing obstructed airflow
  • inflammation and scarring
61
Q

chronic bronchitis FEV1/FEV dx

A

<75% WITH chronic cough

62
Q

Blue bloaters

A
  • chronic bronchitis
  • decreased ventilation
  • increased RV and decreased expiratory flow
  • shunting
  • hypoxemia, hypercapnia, cyanosis, polycythemia
  • cor pulmonale
63
Q

Asthma

A
  • episodic, reversible, obstructive lung disease due to bronchospasms
  • exaggerated inflammatory response to smooth muscles to stimuli
64
Q

extrinsic asthma

A
  • allergic

- mast cells degranulate and release histamines causing inflammatory response and smooth muscle constriction

65
Q

intrinsic asthma

A
  • non-allergen/ non-immune response
  • adult onset
  • often secondary to chronic or recurrent infections of the bronchi, sinuses, tonsils or adenoids
66
Q

Asthma pathogenesis

A
  • an inflammatory response

- inflammatory mediators

67
Q

Bronchial Provocation test

A
  • administration of methacholine to cause smooth muscle contraction
  • evaluates airway sensitivity
  • (+) test 20% decrease in FEV1